| 1) The validation of the eosinophilic versus non-eosinophilic, and of the Th2 predominant versus non-Th2 asthma phenotype, are they persistent over time and do they predict distinct natural histories? |
| 2) Are risk factors, comorbid factors and natural history also governed by specific immune-inflammatory phenotypes? |
| 3) Are there genetic, epigenetic and inflammatory biomarkers of specific phenotypes or characteristics of severe asthma? |
| 4) Is the innate immune response abnormal in severe asthma, and do these contribute to inflammation and remodelling of the airways? |
| 5) What is the relationship between structural determinants, inflammation and airway function in severe asthma, and can imaging be used to noninvasively address these issues? |
| 6) Is there an altered microbiome and virobiome in the airways of severe asthma? |
Th: T-helper cell.